A phase 2 open-label study of the safety and efficacy of weekly dosing of ATL1102 in patients with non-ambulatory Duchenne muscular dystrophy and pharmacology in mdx mice.
Saved in:
| Title: | A phase 2 open-label study of the safety and efficacy of weekly dosing of ATL1102 in patients with non-ambulatory Duchenne muscular dystrophy and pharmacology in mdx mice. |
|---|---|
| Authors: | Woodcock, Ian R.1,2,3 (AUTHOR) ian.woodcock@rch.org.au, Tachas, George4 (AUTHOR), Desem, Nuket4 (AUTHOR), Houweling, Peter J.2,3 (AUTHOR), Kean, Michael5 (AUTHOR), Emmanuel, Jaiman5 (AUTHOR), Kennedy, Rachel1,2,6 (AUTHOR), Carroll, Kate1,2 (AUTHOR), de Valle, Katy1,2,6 (AUTHOR), Adams, Justine2 (AUTHOR), Lamandé, Shireen R.2,3 (AUTHOR), Coles, Chantal2 (AUTHOR), Tiong, Chrystal2 (AUTHOR), Burton, Matthew2 (AUTHOR), Villano, Daniella1 (AUTHOR), Button, Peter7 (AUTHOR), Hogrel, Jean-Yves8 (AUTHOR), Catling-Seyffer, Sarah1,2 (AUTHOR), Ryan, Monique M.1,2,3 (AUTHOR), Delatycki, Martin B.9,10 (AUTHOR) |
| Source: | PLoS ONE. 1/25/2024, Vol. 19 Issue 1, p1-16. 16p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 19326203 |
|---|---|
| DOI: | 10.1371/journal.pone.0294847 |
